Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Sep 11, 2025, 8:33 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Despite beating EPS expectations, the significant guidance cut and sharp drop in shares reflects negative investor sentiment. Historical context shows similar scenarios have led to further declines.
AI summary
What happened, with direct paths to the underlying reporting
Lovesac's Q2 losses of 45 cents beat expectations of 71 cents. Quarterly sales of $160.53M exceeded estimates of $160.23M. EPS guidance for FY2026 was significantly reduced from $0.80-$1.36 to $0.52-$1.05. Shares tumbled 13% in pre-market trading to $18.05. U.S. stock futures showed small gains with Dow up 0.2%.
Lovesac's Q2 losses of 45 cents beat expectations of 71 cents.
Quarterly sales of $160.53M exceeded estimates of $160.23M.
EPS guidance for FY2026 was significantly reduced from $0.80-$1.36 to $0.52-$1.05.
Shares tumbled 13% in pre-market trading to $18.05.
U.S. stock futures showed small gains with Dow up 0.2%.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Lovesac expects a quarterly loss of 46 cents per share, down from 1 cent last year. Projected revenue for Q3 is $154.17 million, slightly higher than last year's $149.91 million.…
Lovesac will report earnings on Sept. 11, expecting a larger loss than last year. Projected revenue of $160.42 million is slightly above last year's $156.59 million. Shares droppe…
Lovesac will report Q1 results on June 12, projecting a wider loss. Analysts expect losses of 71 cents per share, worse than last year's 63 cents. Quarterly revenue is projected a…